Kevin M Farr
CIK 1194262 · CHIEF FINANCIAL OFFICER · last filed 2025-05-05
Kevin M Farr is a CHIEF FINANCIAL OFFICER who has filed 153 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing shows the insider was granted $150.0K of PII on May 5, 2025. Across all open-market trades the lifetime net is −$29.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.7M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MAT price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
M1-1518
EL SEGUNDO, CA 90245
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PII | Director | 22,075 | $64.48 | $1.42M | -$1.54M | 57 | 2025-05-05 |
| Niagen Bioscience, Inc. (CDXC) Delisted | CHIEF FINANCIAL OFFICER | 41,625 | $7.87 | $327.6K | $158.5K | 14 | 2022-08-12 |
| MAT | Chief Financial Officer | 282,013 | $15.03 | $4.24M | -$28.01M | 41 | 2017-08-03 |
| BEC | Director | 5,790 | $5.75 | $33.3K | $97.6K | 40 | 2011-06-22 |
Recent Filings
153 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-05-05 | PII | Grant (A) | +4,320 | $150.0K | EDGAR |
| 2024-04-29 | PII | Grant (A) | +1,801 | $150.0K | EDGAR |
| 2023-10-04 | PII | Grant (A) | +359 | $36.9K | EDGAR |
| 2023-08-07 | PII | Sell (S) | −3,225 | -$429.8K | EDGAR |
| 2023-07-31 | PII | Sell (S) | −1,615 | -$216.9K | EDGAR |
| 2023-07-05 | PII | Grant (A) | +301 | $36.9K | EDGAR |
| 2023-05-01 | PII | Grant (A) | +1,380 | $150.0K | EDGAR |
| 2023-04-05 | PII | Grant (A) | +309 | $34.4K | EDGAR |
| 2023-01-05 | PII | Grant (A) | +342 | $34.4K | EDGAR |
| 2022-10-05 | PII | Grant (A) | +175 | $17.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.